Publications

145. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
K. A. Pervanidis, G. D. D’Angelo, J. Weisner, S. Brandherm and D. Rauh
J. Med. Chem.202467 (8)6052–6063

144. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
T. Kirschner, M. P. Müller and D. Rauh
J. Med. Chem.202467 (8)6044-6051

143. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
A. Teuber, T. Schulz, B. S. Fletcher, R. Gontla, T. Mühlenberg, M-L Zischinsky, J. Niggenaber, J. Weisner, S. B. Kleinbölting, J. Lategahn , S. Sievers, M. P. Müller, S. Bauer and D. Rauh
Nat. Communications202415Article number: 63

142. KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape
T. Mühlenberg, J. Falkenhorst, T. Schulz, B. S. Fletcher, A. Teuber, D. Krzeciesa, I. Klooster, M. Lundberg, L. Wilson, J. Lategahn, M. von Mehren, S. Grunewald, A. I. Tüns, E. Wardelmann, J. K. Sicklick, M. Brahmi, C. Serrano, H. U. Schildhaus, S. Sievers, J. Treckmann, M.C. Heinrich, C. P. Raut, W. B. Ou, A. Marino-Enriquez, S. George, D. Rauh, J. A. Fletcher and S. Bauer
Journal of Clinical Oncology202442 (12)1439-1449

141. Fragtory: Pharmacophore-Focused Design, Synthesis, and Evaluation of an sp3-Enriched Fragment Library
M. Bührmann, S. Kallepu, J. D. Warmuth, J. N. Wiese, C. Ehrt, H, Vatheuer, W. Hiller, C. Seitz, L. Levy, P. Czodrowski, S. Sievers, M. P. Müller, and D. Rauh
J. Med. Chem.202366 (9)6297–6314

140. Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines
T. Grabe, K. Jeyakumar, J. Niggenaber, T. Schulz, S. Koska, S. Kleinbölting, M. E. Beck, M. P. Müller, and D. Rauh
ACS Med. Chem. Lett.202314 (5)591–598

139. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
: L. M. N. Melo, D. Herrera-Rios, D. Hinze, S. Löffek, I. Oezel, R. Turiello, J. Klein, S. Leonardelli, I.-V. Westedt, Y. Al-Matary, S. Egea-Rodriguez, A. Brenzel, M. Bau, A. Sucker, E. Hadaschik, F. Wirsdörfer, H. Hanenberg, N. Uhlenbrock, D. Rauh, J. Poźniak, F. Rambow, J.-C. Marine, M. Effern, N. Glodde, D. Schadendorf, J. Jablonska, M. Hölzel, and I. Helfrich
J. Immunother. Cancer202311e004150

138. Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
L. Goebel, T. Kirschner, S. Koska, A. Rai, P. Janning, S. Maffini, H. Vatheuer, P. Czodrowski, R. S. Goody, M. P. Müller, and D. Rauh
eLife202382184

137. Insights into the Conformational Plasticity of the Protein Kinase Akt1 by Multi-Lateral Dipolar Spectroscopy
J. Stehle, J. Weisner, L. Eichhorn, D. Rauh, and M. Drescher
Chem. Eur. J.2023e202203959

136. A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2
S. Palei, J. Weisner, M. Vogt, R. Gontla, B. Buchmuller, C. Ehrt, T. Grabe, S. Kleinbölting, M. P. Müller, G. H. Clever, D. Rauh, and D. Summerer
RSC Med. Chem.202313(12)1540–1548

135. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
I. Heid, C. Münch, S. Karakaya, S. S. Lueong, A. M. Winkelkotte, S. T. Lifers, L. Godfrey, P. F. Y. Cheung, K. Savvatakis, G. J. Topping, F. Englert, L. Kritzner, M. Grashei, A. Tannapfel, R. Viebahn, H. Wolters, W. Uhl, D. Vangala, E. M. M. Smeets, E. H. J. G. Aarntzen, D. Rauh, W. Weichert, J. D. Hoheisel, S. A. Hahn, F. Schilling, R. Braren, M. Trajkovic‑Arsic, and J. T. Siveke
Cancer Metab.202210(24)

134. Optimization of Covalent MKK7 Inhibitors via Crude Nanomole-Scale Libraries
P. Gehrtz, S. Marom, M. Bührmann, J. Hardick, S. Kleinbölting, A. Shraga, C. Dubiella, R. Gabizon, J. N. Wiese, M. P. Müller, G. Cohen, I. Babaev, K. Shurrush, L. Avram, E. Resnick, H. Barr, D. Rauh*, and N. London*
J. Med. Chem.202265 (15)10341–10356

133. Design and synthesis of Nrf2-derived hydrocarbon stapled peptides for the disruption of protein-DNA-interactions
B. Wiedemann , D. Kamps , L. Depta , J. Weisner, J. Cvetreznik, S. Tomassi, S. Gentz, J.-E. Hoffmann, M. P. Müller, O. Koch, L. Dehmelt, and D. Rauh
PLoS One202217 (6)e0267651

132. Persister state-directed transitioning and vulnerability in melanoma
H. Chauvistré, B. Shannan, S. M. Daignault-Mill, R. J. Ju, D. Picard, S. Egetemaier, R. Váraljai, C. S. Gibhardt, A. Sechi, F. Kaschani, O. Keminer, S. J. Stehbens, Q. Liu, X. Yin, K. Jeyakumar, F. C. E. Vogel, C. Krepler, V. W. Rebecca, L. Kubat, S. S. Lueong , J. Forster, S. Horn, M. Remke, M. Ehrmann, A. Paschen, J. C. Becker , I. Helfrich , D. Rauh, M. Kaiser, S. Gul, M. Herlyn, I. Bogeski, J. N. Rodríguez-López, N. K. Haass, D. Schadendorf, A. Roesch
Nat. Commun.202213Article number: 3055

131. Insight Into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors
J. Lategahn, H. L. Tumbrink, C. Schultz-Fademrecht, A. Heimsoeth, L. Werr, J. Niggenaber, M. Keul, F. Parmaksiz, M. Baumann, S. Menninger, E. Zent, I. Landel, J. Weisner, K. Jeyakumar, L. Heyden, N. Russ, F. Müller, C. Lorenz, J. Brägelmann, I. Spille, T. Grabe, M. P. Müller, J. M. Heuckmann, B. Klebl, P. Nussbaumer, M. L. Sos, and D. Rauh
J. Med. Chem.202265 (9)6643–6655

130. Covalent Allosteric Inhibitors of Akt Generated Using a Click Fragment Approach
L. van der Westhuizen, J. Weisner, A. Taher, I. Landel, L. Quambusch, M. Lindemann, N. Uhlenbrock, M. P. Müller, I. R. Green, S. C. Pelly, D. Rauh, and W. A. L. van Otterlo
Chem Med Chem2022e20210077619

129. Cellular model system to dissect the isoform-selectivity of Akt inhibitors
L. Quambusch, L. Depta, I. Landel, M. Lubeck, T. Kirschner, J. Nabert, N. Uhlenbrock, J. Weisner, M. Kostka, L. M. Levy, C. Schultz-Fademrecht, F. Glanemann, K. Althoff, M. P. Müller, J. T. Siveke, D. Rauh
Nat Commun202112(1)Article number: 5297

128. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain
S. Grunewald, L. R. Klug, T. Muhlenberg, J. Lategahn, J. Falkenhorst, A. Town, C. Ehrt, E. Wardelmann, W. Hartmann, H.-U. Schildhaus, J. Treckmann, J. A. Fletcher, S. Jung, P. Czodrowski, S. Miller, O. Schmidt-Kittler, D. Rauh, M. C. Heinrich, and S. Bauer
Cancer Discov.202111(1)108-125

127. Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach
J. Lategahn, J. Hardick, T. Grabe, J. Niggenaber, K. Jeyakumar, M. Keul, H. L. Tumbrink, C. Becker, L. Hodson, T. Kirschner, P. Klövekorn, J. Ketzer, M. Baumann, S. Terheyden, A. Unger, J. Weisner, M. P. Müller, W. A. L. van Otterlo, S. Bauer, and D. Rauh
J. Med. Chem.202063 (20)11725–11755

126. Conformational selection vs. induced fit: insights into the binding mechanisms of p38α MAP Kinase inhibitors
P. Roser, J. Weisner, J. Stehle, D. Rauh, and M. Drescher
Chem. Commun.2020568818-8821

125. KRasG12C inhibitors in clinical trials: a short historical perspective
L. Goebel, M. P. Müller, R. S. Goody, and D. Rauh
RSC Med. Chem.202011760-770

124. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC
C. Volz, S. Breid, C. Selenz, A. Zaplatina, K. Golfmann, L. Meder, F. Dietlein, S. Borchmann, S. Chatterjee, M. Siobal, J. Schöttle, A. Florin, M. Koker, M. Nill, L. Ozretić, N. Uhlenbrock, S. Smith, R. Büttner, H. Miao, B. Wang, H. C. Reinhardt, D. Rauh, M. Hallek, A. Acker-Palmer, L. C. Heukamp, and R. T. Ullrich
Cell Reports202031107568

123. Spotlight on AKT: Current Therapeutic Challenges
I. Landel, L. Quambusch, L. Depta, and D. Rauh
ACS Med. Chem. Lett.202011(3)225-227

122. Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
L. Quambusch, I. Landel, L. Depta, J. Weisner, N. Uhlenbrock, M. P. Müller, F. Glanemann, K. Althoff, J. T. Siveke, and D. Rauh
Angew. Chem. Int. Ed.2019131(52)18999-19005

121. Inhibition of Osimertinib-Resistant Epidermal Growth Factor Receptor EGFR-T790M/C797S
J. Lategahn, M. Keul, P. Klövekorn, H. L. Tumbrink, J. Niggenaber, M. P. Müller, L. Hodson, M. Flaßhoff, J. Hardick, T. Grabe, J. Engel, C. Schultz-Fademrecht, M. Baumann, J. Ketzer, T. Mühlenberg, W. Hiller, G. Günther, A. Unger, H. Müller, A. Heimsoeth, C. Golz, B. Blank-Landeshammer, L. Kollipara, R. Zahedi, C. Strohmann, J. G. Hengstler, W. van Otterlo, S. Bauer, and D. Rauh
Chemical Science20191010789-10801

120. Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
J. Niggenaber, J. Hardick, J. Lategahn, D. Rauh
J. Med. Chem.201963(1)40-51

119. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules
R. S. Goody, M, P. Müller, and D. Rauh
Cell Chem. Biol.201926 (10)1338-1348

118. Characterization of Covalent Pyrazolopyrimidine–MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)
P. Wolle, J. Engel, S. Smith, L. Goebel, E. Hennes, J. Lategahn, and D. Rauh
J. Med. Chem.201962(11)5541-5546

117. 2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach
M. Schehr, C. Ianes, J. Weisner, L. Heintze, M. P. Müller, C. Pichlo, J. Charl, E. Brunstein, J. Ewert, M. Lehr, U. Baumann, D. Rauh, U. Knippschild, C. Peifer, and R. Herges
Photochem. Photobiol. Sci.2019181398-1407

116. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-mutant Pancreatic and Colorectal Cancer
J. Weisner, I. Landel, C. Reintjes, N. Uhlenbrock, M. Trajkovic-Arsic, N. Dienstbier, J. Hardick, S. Ladigan, M. Lindemann, S. Smith, L. Quambusch, R. Scheinpflug, L. Depta, R. Gontla, A. Unger, H. Müller, M. Baumann, C. Schultz-Fademrecht, G. Günther, A. Maghnouj, M. P. Müller, M. Pohl, C. Teschendorf, H. Wolters, R. Viebahn, A. Tannapfel, W. Uhl, J. G. Hengstler, S. A. Hahn, J. T. Siveke and D. Rauh
Cancer Research201979(9)2367-2378Epub 2019 Mar 11

115. Structural and Chemical Insights into the Covalent-allosteric Inhibition of the Protein Kinase Akt
N. Uhlenbrock, S. Smith, J. Weisner, I. Landel, M. Lindemann, T. A. Le, J. Hardick, R. Gontla, R. Scheinpflug, P. Czodrowski, P. Janning, L. Depta, L. Quambusch, M. P. Müller, B. Engels and D. Rauh
Chemical Science201910(12)3573-3585eCollection 2019 Mar 28

114. Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38α MAPK inhibitors
D. Bartolini*, M. Bührmann*, M. L. Barreca, G. Manfroni, V. Cecchetti, D. Rauh, & F. Galli
Biochemical and Biophysical Research Communications2019511(3)579-586Epub 2019 Feb 27

113. Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c Jun N-Terminal Kinase) Pathway with Covalent Inhibitors
P. Wolle, J. Hardick, S. J.F. Cronin, J. Engel, M. Baumann, J. Lategahn, J. M. Penninger, and D. Rauh
J. Med. Chem.201962(5)2843-2848Epub 2019 Feb 21

112. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives
D. N. do Amaral, J. Lategahn, H. H. Fokoue, E.M.B. da Silva, C. M. R. Sant'Anna, D. Rauh, E. J. Barreiro, S. Laufer, L. M. Lima
Sci Rep2019Jan 9 (1)14

111. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
J. Fassunke, F. Müller, M. Keul, S. Michels, M.A. Dammert, A. Schmitt, D. Plenker, J. Lategahn, C. Heydt, J. Brägelmann, H.L. Tumbrink, Y. Alber, S. Klein, A. Heimsoeth, I. Dahmen, R.N. Fischer, M. Scheffler, M.A. Ihle, V. Priesner, A.H. Scheel, S. Wagener, A. Kron, K. Frank, K. Garbert, T. Persigehl, M. Püslek, S. Haneder, B. Schaaf, E. Rodermann, W. Engel-Riedel, E. Felip, E.F. Smit, S. Merkelbach-Bruse, H.C. Reinhardt, S.M. Kast, J. Wolf*, D. Rauh*, R. Büttner*, M.L. Sos*
Nature Communications20189(1)4655

110. Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38α.
P. Roser, J. Weisner, J.R. Simard, D. Rauh*, M. Drescher*
Chem Comm (Camb)201823;54(85)12057-12060

109. Chemical modulation of transcription factors.
B. Wiedemann, J. Weisner, D. Rauh*
Med Chem Comm201811;9(8)1249-1272eCollection 2018 Aug 1. Review

108. C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
T. Grabe, J. Lategahn, D. Rauh*
ACS Med Chem Lett201823;9(8)779-782eCollection 2018 Aug 9

107. RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics.
P. Wolle, J. Weisner, M. Keul, I. Landel, J. Lategahn*, D. Rauh*
Chem Med Chem20188;13(19)2065-2072Epub 2018 Aug 23

106. Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates.
M. Schmidt, A. Romanovska, Y. Wolf, T.D. Ngyuen, A. Krupp, H.L. Tumbrink, J. Lategahn, J. Volmer, D. Rauh, S. Luetz, C. Krumm, J.C. Tiller*
Bioconjug Chem201815;29(8)2671-2678Epub 2018 Jul 11

105. An Unusual Intramolecular Halogen Bond Guides Conformational Selection.
R. Tesch, C. Becker, M.P. Müller, M.E. Beck, L. Quambusch, M. Getlik, J. Lategahn, N. Uhlenbrock, F.N. Costa, M.D. Polêto, P.S.M. Pinheiro, D.A. Rodrigues, C.M.R.Sant’Anna, F.F. Ferreira, H. Verli, C.A.M. Fraga, D. Rauh*
Angew Chem Int Ed Engl201826;57(31)9970-9975

104. Donated chemical probes for open science.
S. Müller*, S. Ackloo, C.H. Arrowsmith, M. Bauser, J.L. Baryza, J. Blagg, J. Böttcher, C. Bountra, P.J. Brown, M.E. Bunnage, A.J. Carter, D. Damerell, V. Dötsch, D.H. Drewry, A.M. Edwards, J. Edwards, J.M. Elkins, C. Fischer, S.V.Frye, A. Gollner, C.E. Grimshaw, A. Ijzerman, T. Hanke, I.V. Hartung, S. Hitchcock, T. Howe, T.V. Hughes, S. Laufer, V.M. Li, S. Liras, B.D. Marsden, H. Matsui, J. Mathias, R.C. O’Hagan, D.R. Owen, V. Pande, D. Rauh, S.H. Rosenberg, B.L. Roth, N.S. Schneider, C. Scholten, K. Singh Saikatendu, A. Simeonov, M. Takizawa, C. Tse, P.R. Thompson, D.K. Treiber, A.Y. Viana, C.I. Wells, T.M. Willson, W.J. Zuercher, S. Knapp, A. Mueller-Fahrnow*
Elife201820;734311

103. Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level.
P. Wolle, M.P. Müller, D. Rauh*
ACS Chem Biol201816;13(3)496-499

102. Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation.
M.P. Müller, D. Rauh*
Cell Chem Biol201818;25(1)4-6

101. Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.
J. Lategahn, M. Keul, D. Rauh*
Angew Chem Int Ed Engl201823;57(9)2307-2313Epub 2018 Jan 12. Review

100. Inhibitors to overcome secondary mutations in the stem cell factor receptor KIT.
H. Kaitsiotou, M. Keul, J. Hardick, T. Mühlenberg, J. Ketzer, C. Ehrt, J. Krüll, F. Medda, O. Koch, F. Giordanetto, S. Bauer*, Rauh D*
J Med Chem201760(21)8801-15

99. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
J. Engel, S. Smith, J. Lategahn, H.L. Tumbrink, L. Goebel, C. Becker, E. Hennes, M. Keul, A. Unger, H. Müller, M. Baumann, C. Schultz-Fademrecht, G. Günther, J.G. Hengstler, D. Rauh*
J Med Chem201760(18)7725-44

98b. Kovalente Liganden zur Adressierung einer lipophilen Bindetasche in der MAPK p38α
M. Bührmann, J. Hardick, J. Weisner, L. Quambusch and D. Rauh
Angew. Chem.2017129 (43)13415-13419

98a. Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants.
M. Bührmann, J. Hardick, J. Weisner, L. Quambusch, D. Rauh*
Angew Chem Int Ed Engl201756(43)13232-36

97. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.
J. Brägelmann, M.A. Dammert, F. Dietlein, J.M. Heuckmann, A. Choidas, S. Böhm, A. Richters, D. Basu, V. Tischler, C. Lorenz, P- Habenberger, Z. Fang, S. Ortiz-Cuaran, F. Leenders, J. Eickhoff, U. Koch, M. Getlik, M. Termathe, M. Sallouh, Z. Greff, Z. Varga, H. Balke-Want, C.A. French, M. Peifer, H.C. Reinhardt, L. Örfi, G. Kéri, S. Ansén, L.C. Heukamp, R. Büttner, D. Rauh, B.M. Klebl, R.K. Thomas, M.L. Sos*
Cell Rep201719(20)2833-45

96. Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK.
M. Bührmann, B.M. Wiedemann, M.P. Müller, J. Hardick, M. Ecke, D. Rauh*
PLoS ONE201712(9)e0184627

95. Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
S. Tomassi, J. Lategahn, J. Engel, M. Keul, H.L. Tumbrink, J. Ketzer, T. Mühlenberg, M. Baumann, C. Schultz-Fademrecht, S. Bauer, D. Rauh*
J Med Chem201760(6)2361-72

94. Characterization of Covalent-Reversible EGFR Inhibitors.
S. Smith, M. Keul, J. Engel, D. Basu, S. Eppmann, D. Rauh*
ACS Omega20172(4)1563-1575

93. Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34.
L. Robke, L. Laraia, M.A. Carnero Corrales, G. Konstantinidis, M. Muroi, A. Richters, M. Winzker, T. Engbring, S. Tomassi, N. Watanabe, H. Osada, D. Rauh, H. Waldmann*, Y.W. Wu, J. Engel
Angew Chem Int Ed Engl201756(28)8153-57

92. Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK.
J. Halekotte, L. Witt, C. Ianes, M. Krüger, M. Bührmann, D. Rauh, C. Pichlo, E. Brunstein, A. Luxenburger, U. Baumann, U. Knippschild, J. Bischof, C. Peifer*
Molecules201722(4)pii: E522doi: 10.3390/molecules22040522

91b. Optimierte Bindungsdauer am Zielenzym: Typ I½-Inhibitoren der p38α-MAP-Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der R-Spine
H. K. Wentsch, N. M. Walter, M. Bührmann, S. C. Mayer-Wrangowski, D. Rauh, G.J. R. Zaman, N. Willemsen-Seegers, R. C. Buijsman, M. Henning, D. Dauch, L. Zender, and S. A. Laufer
Angew. Chem.2017129 (19)5448-5453

91a. Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine.
H.K. Wentsch, N.M. Walter, M. Bührmann, S. Mayer-Wrangowski, D. Rauh, G.J.R. Zaman, N. Willemsen-Seegers, R.C. Buijsman, M. Henning, D. Dauch, L. Zender, S. Laufer*
Angew Chem Int Ed Engl201756(19)5363-67

90. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
M. Günther, J. Lategahn, M. Juchum, E. Döring, M. Keul, J. Engel, H.L. Tumbrink, D. Rauh, S.A. Laufer*
J Med Chem201760(13)5613-37

89. Design, Synthesis and Biological Evaluation of Novel Type I½ p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency and Prolonged Target Residence Time by Interfering with the R Spine.
N.M. Walter, H.K. Wentsch, M. Bührmann, S.M. Bauer, E. Döring, S. Mayer-Wrangowski, A. Sievers-Engler, N. Willemsen-Seegers, G. Zaman, R. Buijsman, M. Lämmerhofer, D. Rauh, S.A. Laufer*
J Med Chem201760(19)8027-54

89. Drugging the Catalytically Inactive State of RET Kinase in RET-Rearranged Tumors
D. Plenker, M. Riedel, J. Brägelmann, M. A. Dammert, R. Chauhan, R. P. Knowles, C. Lorenz, M. Keul, M. Bührmann, O. Pagel, V. Tischler, A. H. Scheel, D. Schütte, Y. Song, J. Stark, F. Mrugalla, Y. Alber, A. Richters, J. Engel, F. Leeders, J. M. Heuckmann, J. Wolf, J. Diebold, G. Pall, M. Peifer, M. Aerts, K. Gevaert, R. P. Zahedi, R. Buettner, K. M. Shokat, N. Q. McDonald, S. M. Kast, O. Gautschi, R. K. Thomas, and M. L. Sos
Sci. Transl. Med2017)9 (394eaah6144

88. A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
M. Radi, R. Schneider, A.L. Fallacara, L. Botta, E. Crespan, C. Tintori, G. Maga, M. Kissova, A. Calgani, A. Richters, F. Musumeci, D. Rauh, S. Schenone*
Bioorganic & Med Chem Let201626(15)3436-40

87. Insights into the inhibition of drug-resistant EGFR.
J. Engel, C. Becker, J. Lategahn, M. Keul, J. Ketzer, T. Mühlenberg, K. Kollipara, C. Schultz-Fademrecht, R. P. Zahedi, S. Bauer, D. Rauh*
Angew Chem Int Ed Engl201655(36)10909-12

86. Monitoring conformational changes in the receptor tyrosine kinase EGFR.
C. Becker, S. Öcal, H.D. Nguyen, T. Phan, M. Keul, J.R. Simard, D. Rauh*
ChemBioChem201617(11)990-4

85. Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.
J. Engel, J. Lategahn, D. Rauh*
ACS Med Chem Lett20167(1)2-5

84. Special Issue Focused on Two Areas Pertinent to Chemical Biology: Post-Translational Modifications and New Frontiers on Kinases.
D. Rauh
ACS Chem Biol20157(1)2-5

83. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.
J. Schöttle, S. Chatterjee, C. Volz, M. Siobal, A. Florin, D. Rokitta, Y. Hinze, F. Dietlein, D. Plenker, K. König, K. Albus, J.M. Heuckmann, D. Rauh, T. Franz, B. Neumaier, U. Fuhr, L.C. Heukamp, R.T. Ullrich*
Oncotarget20156(36)38458-68

82. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
J. Engel, A. Richters, M. Getlik, S. Tomassi, M. Keul, M. Termathe, J. Lategahn, C. Becker, S. Mayer-Wrangowski, C. Grütter, N. Uhlenbrock, J. Krüll, N. Schaumann, S. Eppmann, P. Kibies, F. Hoffgaard, J. Heil, S. Menninger, S. Ortiz-Cuaran, J.M. Heuckmann, V. Tinnefeld, R.P. Zahedi, M.L. Sos, C. Schultz-Fademrecht, R.K. Thomas, S.M. Kast*, D. Rauh*
J Med Chem201558(17)6844-63

81. Covalent-Allosteric Kinase Inhibitors.
J. Weisner, R. Gontla, L. van der Westhuizen, S. Oeck, J. Ketzer, P. Janning, A. Richters, T. Mühlenberg, Z. Fang, A. Taher, V. Jendrossek, S.C. Pelly, S. Bauer, W.A.L. van Otterlo, D. Rauh*
Angew Chem Int Ed Engl201554(35)10313-6

80. Monitoring ligand induced conformational changes for the identification of estrogen receptor agonists and antagonists.
S.C. Mayer-Wrangowski, D. Rauh*
Angew Chem Int Ed Engl201554(14)4379-82

79. Neuritogenic Militarinone-Inspired 4-Hydroxypyridones Target the Stress Pathway Kinase MAP4K4.
P. Schröder, T. Förster, S. Kleine, C. Becker, A. Richters, S. Ziegler, D. Rauh, K. Kumar, H. Waldmann*
Angew Chem Int Ed Engl201554(42)12398-403

78. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
F. Dietlein, B. Kalb, M. Jokic, E.M. Noll, A. Strong, L. Tharun, L. Ozretić, H. Künstlinger, K. Kambartel, W.J. Randerath, C. Jüngst, A. Schmitt, A. Torgovnick, A. Richters, D. Rauh, F. Siedek, T. Persigehl, C. Mauch, J. Bartkova, A. Bradley, M.R. Sprick, A. Trumpp, R. Rad, D. Saur, J. Bartek, J. Wolf, R. Büttner, R.K. Thomas, H.C. Reinhardt*
Cell2015162(1)146-59

77. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR.
D. Basu, A. Richters, D. Rauh*
Bioorg Med Chem201523(12)2767-80

76. Identification and Further Development of Potent TBK1 Inhibitors
A. Richters, D. Basu, J. Engel, M.S. Ercanoglu, H. Balke-Want, R. Tesch, R.K. Thomas, D. Rauh*
ACS Chem Biol201510(1)289-98

75. Discovery of Inter-Domain Stabilizers - A Novel Assay System for Allosteric Akt Inhibitors.
Z. Fang, J.R. Simard, D. Plenker, H.D. Nguyen, T. Phan, P. Wolle, S. Baumeister, D. Rauh*
ACS Chem Biol201510(1)279-88

74. FLiK: A Direct-Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations.
J.R. Simard*, D. Rauh*
Methods Enzymol2014548147-71

73. Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma.
C. Tintori, A.L. Fallacara, M. Radi, C. Zamperini, E. Dreassi, E. Crespan, G. Maga, S. Schenone, F. Musumeci, C. Brullo, A. Richters, F. Gasparrini, A. Angelucci, C. Festuccia, S. Delle Monache, D. Rauh, M. Botta*
J Med Chem201458(1)347-61

72. Identification of type II and III DDR2 inhibitors.
A. Richters, H.D. Nguyen, T. Phan, J.R. Simard, C. Grütter, J. Engel, D. Rauh*
J Med Chem201457(10)4252-62

71. Correlating structure and ligand affinity in drug discovery: a cautionary tale involving second shell residues.
A. Tziridis, D. Rauh, P. Neumann, P. Kolenko, A. Menzel, U. Bräuer, C. Ursel, P. Steinmetzer, J. Stürzebecher, A. Schweinitz, T. Steinmetzer, M.T. Stubbs*
Biol Chem2014395(7-8)891-903

70. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in squamous-cell lung cancer.
F. Malchers, F. Dietlein, J. Schöttle, X. Lu, L. Nogova, K. Albus, L. Fernandez-Cuesta, J. M. Heuckmann, O. Gautschi, J. Diebold, D. Plenker, M. Gardizi, M. Scheffler, M. Bos, D. Seidel, F. Leenders, A. Richters, M. Peifer, A. Florin, P.S. Mainkar, N. Karre, S. Chandrasekhar, J. George, S. Silling, D. Rauh, T. Zander, R. T. Ullrich, H.C. Reinhardt, F. Ringeisen, R. Büttner, L.C. Heukamp, J. Wolf, R.K. Thomas*
Cancer Discovery20144(2)246-57

69. A special thematic compilation/special issue crossover with Biochemistry,Journal of Medicinal Chemistry, and ACS Medicinal Chemistry Letters focused on kinases.
D. Rauh
ACS Chem Biol20149(3)579-80

68. Metabolically Stable Dibenzo[b,e]oxepin-11(6H)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood.
B. Baur, K. Storch, K.E. Martz, M.I. Goettert, A. Richters, D. Rauh and S.A. Laufer*
J Med Chem201356(21)8561-78

67. Structural characterization of the RLCK family member BSK8: A pseudokinase with an unprecedented architecture.
C. Grütter, S. Sreeramulu, G. Sessa, D. Rauh*
J Mol Biol2013425(22)4455-67

66. Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design.
A. Richters, J. Ketzer, C. Grütter, M. Getlik, R. Schneider, J.M. Heuckmann, S. Heynck, M.L. Sos, A. Gupta, A. Unger, C. Schultz-Fademrecht, R.K. Thomas, S. Bauer*, D. Rauh*
J Med Chem201356(14)5757-72

65. Overcoming compound fluorescence in the FLiK screening assay with red-shifted fluorophores.
R. Schneider, A. Gohla, J.R. Simard, D.B. Yadav, Z. Fang, W.A.L. van Otterlo, D. Rauh*
J Am Chem Soc2013135(22)8400-8

64. Selective Detection of Allosteric Phosphatase Inhibitors.
R. Schneider, C. Beumer, J.R. Simard, C. Grütter, D. Rauh*
J Am Chem Soc2013135(18)6838-4

63. De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
R. Urich, G. Wishart, M. Kiczun, A. Richters, N. Tidten-Luksch, D. Rauh, B. Sherborne, P.G. Wyatt* and R. Brenk*
ACS Chem Biology20138(5)1044-52

62. BSKs are partially redundant positive regulators of brassinosteroid signaling in Arabidopsis.
S. Sreeramulu, Y. Mostizky, H. Nahum, L. Amram, E. Shani, C. Grütter, D. Rauh, N. Ori, G. Sessa*
Plant Journal201374(6)905-19

61. Highly Enantioselective Catalytic Synthesis of Neurite Growth-Promoting Secoyohimbanes.
A.P. Antonchick, S. López-Tosco, J. Parga, S. Sievers, M. Schürmann, H. Preut, S. Höing, H.R. Schöler, J. Sterneckert, D. Rauh, H. Waldmann*
Chemistry & Biology201320(4)500-9

60. Strategies for the Selective Regulation of Kinases with Allosteric Modulators - Exploiting Exclusive Structural Features.
Z. Fang, C. Grütter, D. Rauh*
ACS Chem Biol20138(1)58-70

59. Chemical Biology – current and next challenges.
D. Rauh
ACS Chem Biol20138(1)1-2

58. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
S. Chatterjee, L.C. Heukamp, M. Siobal, J. Schöttle, C. Wieczorek, M. Peifer, D. Frasca, M. Koker, K. König, L. Meder, D. Rauh, R. Büttner, J. Wolf, R.A. Brekken, B. Neumaier, G. Christofori, R.K. Thomas, R.T. Ullrich*
J Clin Invest2013123(4)1732-40

57. Dibenzosuberones as p38 MAP kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.
S. Fischer, H.K. Wentsch, S.C. Mayer-Wrangowski, M. Zimmermann, S.M. Bauer, K. Storch, R. Nieß, S.C. Koeberle, C. Grütter, F.M. Böckler, D. Rauh and S.A. Laufer*
J Med Chem201356(1)241-53

56. Natural product derived fragments for fragment-based ligand discovery.
B. Over, S. Wetzel, C. Grütter, Y. Nakai, S. Renner, D. Rauh, H. Waldmann*
Nat Chem20135(1)21-8

55. A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
M.L. Sos, F. Dietlein, M. Peifer, H. Balke-Want, C. Müller, M. Koker, A. Richters, S. Heynck, J. Schöttle, F. Malchers, J.M. Heuckmann, D. Seidel, L.e Fernandez-Cuesta, P. Eyers, A.P. Antonchick, V.V. Vintonyak, P.M. Schneider, T. Ninomiya, D. Rauh, L.C. Heukamp, R.K. Thomas*
Proc Natl Acad Sci2012109(42)17034-9

54. Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38alpha Inhibitors.
K. Martz, A. Dorn, B. Baur, V. Schattel, M. Goettert, S. Mayer-Wrangowski, D. Rauh, S.A. Laufer*
J Med Chem201255(17)7862-74

53. Design, Synthesis, and Biological Evaluation of Novel Disubstituted Dibenzosuberones as Highly Potent and Selective Inhibitors of p38 Mitogen Activated Protein Kinase.
S.C. Koeberle, S. Fischer, D. Schollmeyer, V. Schattel, C. Grütter, D. Rauh, S.A. Laufer*
J Med Chem201255(12)5868-77

52. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
M. Peifer, L. Fernández-Cuesta, M.L. Sos, J. George, D. Seidel, L.H. Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker, I. Dahmen, C. Müller, D. Di Cerbo, H.U. Schildhaus, J. Altmüller, I. Baessmann, C. Becker, B. de Wilde, J. Vandesompele, D. Böhm, S. Ansén, F. Gabler, I. Wilkening, S. Heynck, J.M. Heuckmann, X. Lu, S.L. Carter, K. Cibulskis, S. Banerji, G. Getz, K.S. Park, D. Rauh, C. Grütter, M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen I, Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M. Brockmann, W. Engel-Riedel, L.A. Muscarella, V.M. Fazio, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D.A. Heideman, P.J. Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O.T. Brustugun, M. Lund-Iversen, J. Sänger, J.H. Clement, A. Soltermann, H. Moch, W. Weder, B. Solomon, J.C. Soria, P. Validire, B. Besse, E. Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P.M. Schneider, M. Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R. Büttner, J. Wolf, P. Nürnberg, S. Perner, L.C. Heukamp, P.K. Brindle, S. Haas, R.K. Thomas*
Nat Genet201244(10)1104-10

51. Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer.
J. Heuckmann, D. Rauh, R.K. Thomas*
J Clin Oncol201230(27)3417-20

50. Change or be changed: Reflections of the workshop 'Future in Medicinal Chemistry'.
R. Brenk*, D. Rauh*
Bioorg Med Chem201215;20(12)3695-7

49. Targeting GSK3 from Ustilago maydis: Type-II kinase inhibitors as potential antifungals.
C. Grütter, J.R. Simard, S.C. Mayer-Wrangowski, P.H. Schreier, J. Pérez-Martín, A. Richters, M. Getlik, O. Gutbrod, C.A. Braun, M.E. Beck,D. Rauh*
ACS Chem Biol201220;7(7)1257-67

48. A direct binding assay for the detection of type IV allosteric inhibitors of Abl.
R. Schneider, C. Becker, J.R. Simard, M. Getlik, N. Bohlke, P. Janning, D. Rauh*
J Am Chem Soc20126;134(22)9138-41

47. Fluorophore labeled kinase detects that bind within the MAPK insert of p38α kinase.
M. Getlik, J.R. Simard, M. Termathe, C. Grütter, M. Rabiller, W.A.L. van Otterlo, D. Rauh*
PLoS ONE20127(7)e39713

46. A chemical genetic approach for covalent inhibition of analog-sensitive Aurora kinase in fission yeast.
A. Koch, H. Rode, A. Richters, D. Rauh*, S. Hauf*
ACS Chem Biol20127(4)723-3

45. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
M. Getlik, C. Grütter, J. R. Simard, H. D. Nguyen, A. Robubi, B. Aust, W. A. L. van Otterlo* and D. Rauh*
Eur J Med2012481-15

44. Skepinone-L: a p38 mitogen activated protein kinase (MAPK) inhibitor with unsurpassed selectivity and outstanding in vivo efficacy.
S.C. Köberle, J. Romir, S. Fischer, A. Köberle, V. Schattel, W. Albrecht, C. Grütter, O. Werz, D. Rauh, T. Stehle, S.A. Laufer*
Nat Chem Biol20118(2)141-43

43. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
J.M. Heuckmann, M. Hölzel, M.L. Sos, S. Heynck, H. Balke-Want, M. Koker, M. Peifer, J. Weiss, C.M. Lovly, C. Grütter, D. Rauh, W. Pao, R.K. Thomas*
Clin Cancer Res201117(23)7394-401

42. Identification of fungal Aurora kinase as a prominent target for N-substituted diaminopyrimidines.
S. Tückmantel, J.N. Greul, P. Janning, A. Brockmeyer, C. Grütter, J.R. Simard, O. Gutbrod, M.E. Beck, K. Tietjen, D. Rauh*, P.H. Schreier*
ACS Chem Bio20116(9)926-33

41. Identification and further development of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
V.V. Vintonyak, K. Warburg, B. Over, K. Hübel, D. Rauh, H. Waldmann*
Tetrahedron201167(35)6713-29

40. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
P.S. Hammerman, M.S. Sos, A.H. Ramos, C. Xu, A. Dutt, W. Zhou, L.E. Brace, B.A. Woods, W. Lin, J. Zhang, X. Deng, S.M. Lim, S. Heynck, M. Peifer, J.R. Simard, M.S. Lawrence, R.C. Onofrio, H.B. Salvesen, D. Seidel, T. Zander, J.M. Heuckmann, A. Soltermann, H. Moch, M. Koker, F. Leenders, F. Gabler, S. Querings, S. Ansén, E. Brambilla, C. Brambilla, P. Lorimier, O.T. Brustugun, A. Helland, I. Petersen, J.H. Clement, H. Groen, W. Timens, H. Sietsma, E. Stoelben, J. Wolf, D.G. Beer, M.S. Tsao, M. Hanna, C. Hatton, M.J. Eck, P.A. Jänne, B.E. Johnson, W. Winckler, H. Greulich, A.J. Bass, J. Cho, D. Rauh, N.S. Gray, K.K. Wong, E.B. Haura, R.K. Thomas* and M. Meyerson*
Cancer Discovery20111(1)78-89

39. Using small molecules to target protein phosphatases.
V.V. Vintonyak, H. Waldmann*, D. Rauh*
Bioorg Med Chem201119(7)2145-55

38. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino) isoquinoline-4-carbonitriles as inhibitors of Myosine Light Chain Kinase and Epidermal Growth Factor Receptor.
H. Rode, M.L. Sos, C. Grütter, S. Heynck, J.R. Simard, D. Rauh*
Bioorg Med Chem201119(1)429-39

37. Characterization of irreversible kinase inhibitors by detecting fluorescent changes during covalent bond formation.
S. Klüter, J. Simard, H. Rode, C. Grütter, M. Rabiller, W. van Otterlo, D. Rauh*
ChemBioChem201011(18)2557-6

36. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer.
J. Weiss, M. Sos*, D. Seidel, M. Peifer, T. Zander, J. Heuckmann, R. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schöttle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. Heukamp, H. Balke-Want, S. Ansén, D. Rauh, I. Baessmann, J. Altmüller, Z.Wainer, M. Conron, G. Wright, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Solberg, O. T. Brustgun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sänger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nürnberg, S. Perner, R. Thomas*
Sci Transl Med20102(62)62-9

35. RAF kinase inhibitors in cancer treatment: like a bull in a china shop?
A. Robubi, H. Waldmann, D. Rauh*
ChemBioChem201011(12)1645-8

34. Identification of Spiro-fused Indolin-2-one-thiazolidinones as Potent and Selective Inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.
V.V. Vintonyak, K. Warburg, H. Kruse, S. Grimme, K. Hübel, D. Rauh and H. Waldmann*
Angew Chem Int Ed Engl201049(34)5902-5

33. Highly Enantioselective Synthesis and Cellular Evaluation of Natural Product-Inspired Spirooxindoles.
A.P. Antonchick, C. Gerding-Reimers, M. Catarinella, S. Ziegler, D. Rauh and H. Waldmann*
Nature Chemistry20102(9)735-40

32. Small-molecule inhibition of APT1 affects Ras localization and signaling.
F.J. Dekker, O. Rocks, N. Vartak, S. Menninger, C. Hedberg, R. Balamurugan, S. Wetzel, S. Renner, M. Gerauer, B. Schölermann, M. Rusch, J.W. Kramer, D. Rauh, G.W. Coates, L. Brunsveld, P.I. Bastiaens*, H. Waldmann*
Nat Chem Biol20106(6)449-56

31. A Scaffold-Tree-Merging Strategy for Prospective Bioactivity Annotation of gamma-Pyrones.
S. Wetzel, W. Wilk, S. Chammaa, B. Sperl, A. Roth, A. Yektaoglu, S. Renner, T. Berg, C. Arenz, A. Giannis, T.I. Oprea, D. Rauh, M. Kaiser, H. Waldmann*
Angew Chem Int Ed Engl201049(21)3666-70

30. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of EGFR.
V. Pawar, M. Sos, H. Rode, M. Rabiller, S. Heynck, W. van Otterlo, R. Thomas, D. Rauh*
J Med Chem201053(7)2892-901

29. Proteus in the World of Proteins: Conformational Changes in Protein Kinases.
M. Rabiller, M. Getlik, S. Klüter, S. Tückmantel, A. Richters, J.R. Simard, D. Rauh*
Archiv der Pharmazie (Weinheim)2010343(4)193-206

28. Fluorophore-labeling of the glycine-rich loop as a method of identifying inhibitors which bind to active and inactive kinase conformations.
J.R. Simard, M. Getlik, C. Grütter, R. Schneider, S. Wulfert, D. Rauh*
J Am Chem Soc2010132(12)4152-60

27. Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.
M. Peifer, J. Weiss, M.L. Sos, M. Koker, S. Heynck, C. Netzer, S. Fischer, H. Rode, D. Rauh, J. Rahnenführer and R.K. Thomas*
PLoS ONE20105(1)e8919

26. Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation.
M.L. Sos, H. Rode, S. Heynck, M. Peifer, F. Fischer, S. Klüter, V. Pawar, C. Reuter, J. Heuckmann, J. Weiss, L. Ruddigkeit, M. Rabiller, M. Koker, J. Simard, M. Getlik, R.K. Thomas* and D. Rauh*
Cancer Research201070(3)868-74

25. Structure-based development of a displacement assay for the detection of stabilizers of inactive kinase conformations.
S. Klüter, C. Grütter, M. Rabiller, V. Pawar, M. Getlik, J.R. Simard, D. Rauh*
J Med Chem201053(1)357-67

24. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38α.
J.R. Simard, C. Grütter, V. Pawar, B. Aust, A. Wolf, M. Rabiller, S. Wulfert, A. Robubi, S. Klüter, C. Ottmann, D. Rauh*
J Am Chem Soc2009131(51)18478-88

23. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
M.L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. Heuckmann, M. Koker, S. Heynck, I. Stückrath, J. Weiss, F. Fischer, A. Goel, L. Regales, K. Politi, S. Perera, M. Getlik, L. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K. Shokat, W. Sellers, D. Rauh, C. Orr, K. Hoeflich, L. Friedman, K. Wong, W. Pao, R. Thomas*
Proc Natl Acad Sci200910618351-6

22. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
J.R. Simard, M. Getlik, C. Grütter, V. Pawar, D. Rauh*
J Am Chem Soc2009131(37)13286-96This article was highlighted in Faculty of 1000 Biology

21. Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc.
M. Getlik, C. Grütter, J. Simard, S. Klüter, M. Rabiller, H.B. Rode, A. Robubi, D. Rauh*
J Med Chem200952(13)3915-26

20. A new screening assay for allosteric inhibitors of cSrc.
J.R. Simard, S. Klüter, C. Grütter, M. Rabiller, H.B. Rode, D. Rauh*
Nat Chem Biol20095(6)394-6This article was highlighted in Faculty of 1000 Biology

19. Predicting drug activity in non-small cell lung cancer based on genetic lesions.
M.L. Sos, K. Michel, T. Zander, J. Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stückrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W.F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenführer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B.A. Weir, T.-H. Chen, H. Greulich, J. Barretina, G.I. Shapiro, L.A. Garraway, A.F. Gazdar, J.D. Minna, M. Meyerson*, K.-K. Wong* and R.K. Thomas*
J Clin Invest200919(6)1727-40

18. Chemical and Structural Biology to Direct the Repurposing of Sulindac.
J.R. Simard, D. Rauh*
ChemMedChem200941793-5

17. The Therapeutic Potential of Phosphatase Inhibitors.
V.V. Vintonyak, A.P. Antonchick, D. Rauh*, H. Waldmann*
Curr Opin Chem Biol200913(3)272-83

16. Bioactivity-Guided Mapping of and Navigation in Chemical Space.
S. Renner, W. van Otterlo, M. Dominguez Seoane, S. Möcklinghoff, B. Hofmann, S. Wetzel, A. Schuffenhauer, P. Ertl, T. Oprea, D. Steinhilber, L. Brunsveld, D. Rauh, H. Waldmann*
Nat Chem Biol20095(8)585-92

15. Interactive Exploration of Chemical Space with Scaffold Hunter.
S. Wetzel, K. Klein, S. Renner, D. Rauh, T. Oprea, P. Mutzel, H. Waldmann*
Nat Chem Biol20095(8)581-3

14. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
A. Michalczyk, S. Klüter, H.B. Rode, J.R. Simard, C. Grütter, M. Rabiller, D. Rauh*
Bioorg Med Chem200816(7)3482-8

13. Human carbonyl reductase 1 is an S-nitrosogluathione reductase.
R. Bateman, D. Rauh, B. Tavshanjian, and K.M. Shokat*
J Biol Chem2008283(51)35756-62

12. Biochemical and structural analysis of substrate promiscuity in plant Mg2+-dependent O-methyltransferases.
J.G. Kopycki, D. Rauh (co-first author), A.A. Chumanevich, P. Neumann, T. Vogt, and M.T. Stubbs*
J Mol Biol2008378(1)154-64

11. ATP competitive inhibitors of d-alanine-d-alanine ligase based on protein kinase inhibitor scaffolds.
G. Triola, S. Wetzel, B. Ellinger, M. Koch, K. Hübel, D. Rauh, and H. Waldmann*
Bioorg Med Chem200917(3)1079-87

10. Linking chemistry and biology for the study of protein function.
D. Rauh* and H. Waldmann
Angew Chem Int Ed Engl200746(6)826-9

09. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
J.A. Blair, D. Rauh, C. Kung, C.H. Yun, Q.W. Fan, H. Rode, C. Zhang, M.J. Eck, W.A. Weiss, and K.M. Shokat*
Nat Chem Biol20073(4)229-38

08. Glutathione traps formaldehyde by formation of a bicyclo[4.4.1]undecane adduct.
R. Bateman, D. Rauh, and K.M. Shokat*
Org Biomol Chem20075(20)3363-70

07. Structure and properties of a re-engineered homeodomain protein-DNA interface.
M.D. Simon, M.E. Feldman, D. Rauh, A.E. Maris, D.E. Wemmer, and K.M. Shokat*
ACS Chem Biol20061(12)755-60

06. An unbiased cell morphology-based screen for new, biologically active small molecules.
M. Tanaka, R. Bateman, D. Rauh, E. Vaisberg, S. Ramachandani, C. Zhang, K.C. Hansen, A.L. Burlingame, J.K. Trautman, K.M. Shokat*, and C.L. Adams
PLoS Biol20053(5)e128

05. Understanding protein-ligand interactions: the price of protein flexibility.
D. Rauh, G. Klebe, and M.T. Stubbs*
J Mol Biol2004335(5)1325-41

04. ZZ made EZ: influence of inhibitor configuration on enzyme selectivity.
D. Rauh, G. Klebe, J. Stürzebecher, and M.T. Stubbs*
J Mol Biol2003330(4)761-70

03. New cyanopeptide-derived low molecular weight thrombin inhibitors.
G. Radau*, J. Gebel, and D. Rauh
Arch Pharm (Weinheim)2003336(8)372-80

02. Trypsin mutants for structure-based drug design: expression, refolding and crystallisation.
D. Rauh, S. Reyda, G. Klebe, and M.T. Stubbs*
Biol Chem2002383(7-8)1309-14

01. Synthesis of a cyanopeptide-analogue with trypsin activating properties.
G. Radau* and D. Rauh
Bioorg Med Chem Lett200010(8)779-81

Coordinator

Project contact

Publications